IMAC Holdings, Inc. Material Event - What Happened

Hey there! Let's break down some important news about IMAC Holdings, Inc. in a way that makes sense, without all the confusing finance talk. Think of this as me explaining it to you over coffee.

1. What happened? (in plain English - the actual event)

IMAC Holdings gave up a big part of its business: Ignite Proteomics LLC. This included all its assets, patents, and operations. Ignite developed new ways to diagnose and treat diseases. It used proteomics, the study of proteins. IMAC did this because it could not pay its $36 million in secured loans. By giving up Ignite Proteomics, IMAC's debt to its lenders is now gone. This cleared the main loan amount, interest, and other fees. It's like giving back a car you can't afford the payments on, and the dealership agrees you don't owe them anything anymore.

This isn't the end of Ignite, though. The lenders are selling it to Aditxt, Inc. (ADTX). The sale is worth at least $35 million. ADTX did this by giving $36 million in new special preferred stock to the lenders. The lenders are paying for this stock by giving Ignite's assets to ADTX. They had just received these assets from IMAC. So, IMAC loses Ignite, and its $36 million debt is gone. ADTX gains Ignite Proteomics, growing its biotech business. This is not a small, everyday event. It's a big change that affects how the company works and its future.

2. When did it happen?

This news came out on March 19, 2026. IMAC filed an official report with the SEC that day. The main agreements for this big change were signed on March 11, 2026.

3. Why did it happen? (context and background)

So, why did this big thing happen? IMAC Holdings could not pay its $36 million in secured loans. These loans were a heavy financial load. To settle this debt, IMAC gave up Ignite Proteomics LLC to its lenders. This move let IMAC get rid of a lot of debt from its books.

Before this deal, IMAC ran medical clinics for regenerative rehabilitation. They offered non-surgical treatments for pain and age-related issues. Ignite Proteomics, however, was IMAC's biotech research arm. By selling Ignite, IMAC is getting rid of its biotech part. This helps solve its debt problems.

For ADTX, this was a chance to buy Ignite Proteomics. It helps ADTX grow its biotech business, especially in proteomics. Think of it like a business making a big decision to either get stronger, solve a problem, or grab a new opportunity.

4. Why does this matter? (impact and significance)

Okay, so why should you care about this? This isn't just some boring corporate announcement. This event could greatly change IMAC's operations and finances.

• For IMAC: IMAC is getting rid of about $36 million in secured debt. This is a big win for its finances and stability. But it also loses Ignite Proteomics, an important part of its business. Ignite was its biotech research arm for proteomics. The company will be much smaller. Its focus will shift to its main business. IMAC will now focus on running medical clinics. These clinics offer regenerative rehabilitation and non-surgical pain relief. It's like a major 'reset' button, but with fewer pieces on the board and a clearer, albeit smaller, operational scope.
• For its Lenders (Noteholders): The lenders get their money back (or something worth the same). They took Ignite Proteomics from IMAC. Then they gave it to ADTX for $36 million in ADTX preferred stock. This settles their investment in IMAC's secured loans.
• For ADTX: ADTX is growing its business by buying Ignite Proteomics. They gain new services, tech, and patents in proteomics. This fits their overall biotech plan. This acquisition is valued at at least $35 million.

5. Who is affected? (employees, customers, investors, etc.)

A big event like this usually sends ripples. Here's who might feel it:

• Investors (that's you!): Your IMAC Holdings shares (ticker BACK) are part of a very different company now. Its assets are much smaller after giving up Ignite Proteomics. But its debt is also $36 million lighter. This will change how the market sees IMAC's future profits and growth. IMAC now only focuses on its rehab clinics.
• Employees of Ignite Proteomics LLC: Their employer has changed owners, moving from IMAC to ADTX. This could mean changes in management, company culture, or future plans under ADTX.
• Customers of Ignite: Customers will now be working with ADTX. This might mean changes in services or products as ADTX takes over Ignite.
• Management/Leadership of IMAC: This was a big decision to solve financial problems. Their focus will now be only on IMAC's remaining businesses. They will focus on how well its rehab clinics perform and grow.
• ADTX and its Investors: ADTX is expanding its business by buying Ignite Proteomics. They gain valuable patents and knowledge in proteomics. This could bring new ways to make money and an edge over rivals.

6. What happens next? (immediate and future implications)

So, what's the immediate fallout, and what about down the road?

• Immediately: Ignite Proteomics' assets are transferring to the lenders and then to ADTX. IMAC's books will show $36 million less in secured debt. This greatly improves its financial strength. Analysts will likely share their thoughts on IMAC's future. They will look at its ability to make money from its clinics.
• In the near future: IMAC will be a smaller, more focused company. It will focus only on its rehab clinics. ADTX will start adding Ignite Proteomics into its biotech business. It aims to use Ignite's proteomics technology.
• Long-term: This event will completely change IMAC Holdings. Its finances and growth depend on how its clinics perform. This is without the biotech part. For ADTX, this buy could be a big step in its long-term growth plan. It could open new markets or improve its products through proteomics research. It sets a new course for the company.

7. What should investors/traders know? (practical takeaways)

Alright, for you day traders and casual investors, here's the lowdown:

• Major Transformation: This is not a minor adjustment. IMAC is changing a lot. It gave up a big asset (Ignite Proteomics) to clear $36 million in debt.
• Debt Relief vs. Asset Loss: Clearing $36 million in debt helps IMAC's finances. But losing Ignite means its ways to make money and its operations will shrink. Investors should know IMAC now just runs regenerative rehabilitation clinics.
• Volatility Alert: Expect IMAC's stock price (BACK) to be more jumpy than usual for a while. Big news often causes big price swings. People react to the new, smaller, debt-free IMAC.
• New Focus: Investors should now look at IMAC based on its remaining medical clinics. Consider their plans for growth and profit. Don't judge it by its old biotech business. Look at the rehab market and IMAC's place in it. See if it can make enough cash.
• ADTX Opportunity: If you like ADTX, this is a smart growth move for them. The deal is worth at least $35 million. It grows their presence in proteomics.
• Don't Panic (or Get Overly Excited): Big news can trigger strong emotions. Try to stay rational. Watch IMAC's remaining business for trends. Also watch how ADTX brings in Ignite. Don't make quick decisions based on first reactions.

This is a big moment for IMAC Holdings. Understanding it simply helps you make smart choices.